ImmunityBio (IBRX) Financial Analysis & Valuation | Quarter Chart
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells... more
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $8.88B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Richard Gerald Adcock |
| IPO Date | 2015-07-28 | CAGR | 54.76% |
| Employees | 688 | Website | immunitybio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.03% | Total Yield | 0.03% |
IBRX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $10.38B | P/E | -8.74 | Forward P/E | -66.95 | PEG | — |
| P/S | 604.82 | P/B | -95.91 | P/CF | -721.7 | P/FCF | -709.33 |
| Sales | $165.79M | Sales 1Y | 192.92% | Sales 3Y | 27905.41% | Sales 5Y | 25406.46% |
| EPS | $-0.97 | EPS 1Y | 110.14% | EPS 3Y | -20.2% | EPS 5Y | 23.24% |
| Sales QoQ | 15.91% | EPS QoQ | -64.52% | Sales QoQ Avg | 18.03% | EPS QoQ Avg | 196.27% |
| Gross Margin | 94.63% | Operating Margin | -151.88% | Profit Margin | -598.56% | ROCE | -45.63% |
| ROA | -158% | ROE | 135% | Altman Z Score | -0.09 | Piotroski Score | 4 |
| Current Ratio | 4.66 | Quick Ratio | 4.66 | Cash Ratio | 0.99 | Op. CF Ratio | -0.87 |
| Debt/Equity | -0.04 | Debt/Assets | 0.06 | Lt Debt/Equity | -0.03 | Lt Debt/Cap. | -0.03 |
| Intrst Cov. | -3.64 | Inventory Turnover | — | Asset Turnover | 0.26 | Receivables Turnover | — |
| Enterprise Value | $10.38B | P/E Ratio | -8.74 |
| Forward P/E | -66.95 | PEG Ratio | — |
| P/S Ratio | 604.82 | P/B Ratio | -95.91 |
| P/CF Ratio | -721.7 | P/FCF Ratio | -709.33 |
| EPS | $-0.97 | EPS Growth 1Y | 110.14% |
| EPS Growth 3Y | -20.2% | EPS Growth 5Y | 23.24% |
| Revenue Growth 1Y | 192.92% | Gross Margin | 94.63% |
| Operating Margin | -151.88% | Profit Margin | -598.56% |
| ROE | 135% | ROA | -158% |
| ROCE | -45.63% | Current Ratio | 4.66 |
| Quick Ratio | 4.66 | Cash Ratio | 0.99 |
| Debt/Equity | -0.04 | Interest Coverage | -3.64 |
| Altman Z Score | -0.09 | Piotroski Score | 4 |
ImmunityBio (IBRX) valuation & financials
ImmunityBio (IBRX) has a market capitalization of $8.88B and trades at a price-to-earnings ratio of -8.7. It operates in the Healthcare sector (Biotechnology).
ImmunityBio's revenue grew +192.9% over the last year.
ImmunityBio's next earnings report is scheduled for November 3, 2026 before market open (provider scheduled date); analysts estimate EPS of $-0.08. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)